{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Cost-Effectiveness of UDCA Prophylaxis in Preventing Symptomatic Gallstone Disease: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Conducted as a multicentre, double-blind, randomised placebo-controlled superiority trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients scheduled for laparoscopic RYGB or sleeve gastrectomy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive 900 mg UDCA or placebo for 6 months"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the cost-effectiveness and cost-utility of ursodeoxycholic acid (UDCA) prophylaxis for preventing symptomatic gallstone disease"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of symptomatic gallstone disease within 24 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 985 patients were enrolled between January 2017 and October 2018"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "705 analysed in the modified intention-to-treat analysis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "UDCA prophylaxis significantly reduced the risk of symptomatic gallstone disease (relative risk 1.06, 95% CI 1.02 to 1.11; P = 0.002)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported, with mild gastrointestinal side-effects occurring in 3% of the UDCA group and 1% of the placebo group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXX"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]"
      }
    },
    "total_score": 25,
    "max_score": 25
  },
  "model": "gpt-4o"
}